<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Accelerating Cancer Drug Discovery with Digital Pathology-Based Biomarker Analysis

Accelerating Cancer Drug Discovery with Digital Pathology-Based Biomarker AnalysisDigital pathology is an innovative technology that is transforming the field of modern pathology.

The practice of pathology has traditionally involved the analysis of tissue samples (typically fixed on glass slides) by trained pathologists.

While this workflow has long-been the gold standard for the diagnosis of many diseases, including cancer, it carries an inherent level of variability due to human error and subjectivity.

These drawbacks can reduce diagnostic accuracy and can also impact turnaround time since the traditional workflow was not intended to support a high throughput analysis.

In this post, you will learn about the concept of digital pathology, why pathology practices are embracing this new technology, and how it can be used to accelerate cancer drug discovery by strengthening your pathology-based biomarker analysis.

What is Digital Pathology?

Advances in digital pathology technologies have overcome many of the challenges associated with traditional glass slide workflows. Broadly, digital pathology is an umbrella term that refers to the capture, interpretation and sharing of digitized pathology specimens.

Although not a new concept, the introduction of powerful whole slide imaging (WSI) technologies has enabled the digitization of an entire specimen at diagnostic quality. In some cases, digitized slides may provide superior resolution of certain features that aid in diagnosis.

The power of the technology is unlocked when combined with powerful AI algorithms based on machine learning and/or deep learning.

Implementation of these tools permits more detailed and complex analyses, including deeper analyses of cell populations within a tumor microenvironment (TME), while reducing errors and intra- and inter-observer variability, ultimately leading to more highly accurate assessments.

Integration with advanced data management systems, such as cloud-based software solutions, allows for easier access to samples and facilitates collaboration on a massive scale.

The Application of Digital Pathology-Based Biomarker Analysis

It is no secret that biomarkers are playing an increasingly important role in all facets of cancer drug discovery and development. This is because many new oncology drugs are being developed as precision medicines, where a patient’s biomarker profile determines the right drug for that patient.

Thus, the pharmaceutical industry is integrating biomarker strategies earlier in their R&D programs so they can maximize the chances of identifying biomarkers that successfully stratify patients based on who is most likely to respond or develop resistance.

Biomarkers can be identified to support efficacy, safety, and/or pharmacodynamics and mechanisms of action (MoA), all of which can be challenging to identify, but they can be immensely informative.

Digital pathology offers many benefits to biomarker discovery and analysis.

In particular, AI-based algorithms are now capable of generating quantitative data on drug target expression as well as the density and distribution of single or multiple markers that would be difficult to achieve by the human eye. This is especially important given that many tumors exhibit tumor heterogeneity with some markers expressed in only a small subpopulation of cells.

Traditional pathology can be cumbersome even when interpreting a small number of samples. This task becomes even more challenging for biomarker analysis which typically involves large volumes of tissue samples.

As such, one of the main advantages of digital pathology is the ability to handle the automated analysis of complex datasets comprised of large numbers of individually scanned slides or tissue microarrays (TMAs). Therefore, the use of a digital pathology in biomarker analysis can streamline the workflow, leading to quicker results that can be used to drive downstream decisions.

Implementation of digital pathology has also made important contributions to the field of immuno-oncology (I/O). It is now well recognized that the success of immunotherapy depends on the close and dynamic interaction between tumor cells and other cell populations within the TME. The ability to achieve comprehensive spatial analysis of biomarkers with digital pathology enables researchers to better understand the role of this relationship for the development of new and more effective I/O agents.

Technologies for Digital Pathology-Based Biomarker Analysis

A variety of methods are currently used for tissue biomarker detection. These include basic stains that differentiate different cellular compartments (e.g., H&E) or molecular assays such as immunohistochemistry (IHC) or immunofluorescence (IF) for protein biomarkers. Despite advancements in sequencing technologies, methods such as in situ hybridization (ISH) with chromogenic (CSH) or fluorescent (FISH) options remain popular for the detection of RNA/DNA biomarkers.

Since the majority of tissue biomarkers are protein-based, robust IHC and IF protocols have been developed for a number of important cancer targets. These include:

  • Tumor associated antigens (TAAs), such as growth factor receptors (e.g., EGFR, HER2)
  • Cancer mechanism markers such as tumor proliferation or apoptosis (Ki67, Cleaved Caspase-3), angiogenesis (CD31, VEGF)
  • Immune checkpoint inhibitors (ICIs) PD-1 and PD-L1 which can predict response to immunotherapy in some cancer types.

However, chromogenic IHC is limited to a single-marker which renders it unsuitable for modern biomarker studies which often requires detection of multiple markers simultaneously. While serial-section protocols can overcome some of these limitations to a degree, progress in multiplex staining along with advancements in digital pathology imaging and analysis tools have redefined what is now possible for biomarker research.

Detection of multiple protein targets can be accomplished by both IHC and IF, although fluorescent-based assays provide better signal separation which allows for higher complexity and more accurate quantitation.

This is especially important in analyses that rely on very limited tissue samples and can conserve precious samples for other analyses.

The basic principle of multiplexing involves staining of multiple proteins with specific antibodies that are directly or indirectly tagged with distinct chromogens or fluorophores. Depending on the technology and complexity, this can be achieved in a single-step or more commonly, multiple cycles of labeling, imaging, antibody stripping and re-labelling.

Tyramide Signal Amplification (TSA)-based multiplex IHC is one of the most popular methods for the simultaneous detection of multiple proteins. In this system;

  1. A protein target is labelled with a primary antibody followed by a secondary antibody conjugated with horseradish peroxidase (HRP)
  2. Incubation with a fluorophore-conjugated tyramide molecule results in the formation of covalent bonds with tyrosine residues on the protein target
  3. The permanent deposition of fluorophore enables removal of antibodies without loss of fluorescent signal and permits labelling of the next protein of interest.

Importantly, one of the benefits of this approach is that multiple rounds of staining can be carried out using antibodies from the same species. This method is capable of detecting low abundance proteins since fluorophore-conjugated TSA molecules emit a robust signal.

The TSA-based multiplex IHC method has been extensively used for biomarker analysis in I/O applications.

For example, a recent meta-analysis of studies evaluating PD-1/PD-L1 proximity, CD8+ T-cell density in the TME and markers of T cell activation found that multiplex staining was superior to single-staining or other methods (e.g., gene expression profiling) in predicting response to checkpoint inhibitor therapy.

Digital Imaging Platforms for Biomarker Evaluation

There are many commercial and open-source digital analysis platforms available, each with its own set of strengths and weaknesses. ImageJ, CellProfiler, and QuPath are some of the most used open‐source platforms, while HALOTM (by Indica Laboratories) is a professional quantitative pathology option that offers modules for quantification of a variety of biomarker types and supports cellular, tissue, and spatial analysis.

It is highly recommended to consult with experts in digital pathology prior to selecting a tool, so that you have the best chance at selecting the right tool for your specific research questions.

The preparation of high-quality digitized representations of your tissue glass slides is an important factor in developing high quality data. This involves a multistep and complex process that requires strict quality control for each procedure.

Variables to consider when preparing your slides include:

  • Fixation protocols and antigen sensitivity
  • Tissue processing standard operating procedure (SOP)
  • Tissue section thickness
  • Staining consistency
  • Coverslip material

Lastly, interpretation of chromogenic or fluorescent data from pixels requires an understanding of the settings used to capture, save, and store the images.

This concept also holds true with the use of AI-based algorithms for analysis. Although many image analysis programs come with ‘ready to go’ algorithms/modules, these often need to be adjusted to suit specific research needs.

Conclusion

The opportunity to accelerate cancer drug discovery with digital pathology-based biomarker analysis holds tremendous potential for selecting cancer drug candidates with the most potential for clinical success, including immuno-oncology agents.

The move towards a digital and automated framework reduces the impacts of human error and subjectivity while fostering greater collaboration among researchers for more efficient drug discovery and development.

Crown Bioscience has extensive experience in the use of digital pathology for supporting preclinical biomarker programs for cancer drug discovery and development. Our advanced digital pathology services are designed to help companies accelerate their translational biomarker discovery. Please visit our digital pathology services site to learn more about our expertise in this area.


Related Posts